Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

FDA Considering Use of Off-Label Data for Drug Approvals

December 30, 2021

The U.S. Food and Drug Administration (FDA) signaled its willingness this month to use off-label information in approving new indications for drugs in the future. Currently, the FDA requires a controlled research study before the agency will approve drugs for specific uses. Doctors may then prescribe these drugs for off-label uses not approved by the FDA, but the data on these uses is considered insufficient to meet the agency's regulatory standards.

Rajeshwari Sridhara, PhD, of the FDA's Center for Drug Evaluation and Research, made the announcement at a conference on the use of "real-world data" collected outside of clinical trials. Dr. Sridhara suggested that the agency would need to have the ability to audit off-label data before it would consider using them for drug approvals, adding that the agency would likely consider the rarity and severity of a disease when making these judgments.

"I don't think we are there yet, but that doesn't mean we will never accept [it]," said Dr. Sridhara.

Source: STAT News, July 10, 2018.

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
November 2024

Advertisement intended for health care professionals

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals